Mereo BioPharma(MREO) - 2025 Q1 - Quarterly Report

Financial Performance - Total operating expenses for Q1 2025 were $11.2 million, an increase of$1.3 million from $9.9 million in Q1 2024[104] - Net loss before income tax for Q1 2025 was$12.9 million, compared to $9.0 million in Q1 2024, reflecting a$4.2 million increase[104] - The accumulated deficit as of March 31, 2025, was $472.0 million, with expectations of continued significant operating losses[128] - Cash used in operating activities increased to$8.3 million in Q1 2025 from $8.0 million in Q1 2024[123] - The net foreign exchange loss for Q1 2025 was$2.8 million, compared to a gain of 0.6 million in Q1 2024, due to currency fluctuations[113] Expenses - Research and development (R&D) expenses decreased by 0.1 million to $3.9 million in Q1 2025, primarily due to a$1.2 million decrease in expenses for alvelestat[106][107] - General and administrative expenses increased by $1.4 million to$7.3 million in Q1 2025, mainly due to a prior reimbursement reduction[109] Funding and Capital Requirements - The company anticipates needing additional external funding to complete development plans and potentially commercialize selected rare disease products[116][117] - The company expects existing cash and cash equivalents to fund clinical trials, operating expenses, and capital expenditures into 2027[130] - Future capital requirements will depend on factors such as developing additional product candidates and seeking regulatory approvals[131] - The company may need to obtain substantial additional funds to achieve business objectives, which may not be available on acceptable terms[133] - Future debt or preferred equity financing may involve agreements that limit the company's actions and could dilute shareholder ownership[134] Revenue and Business Objectives - Revenues will be derived from development milestones or sales of successfully developed and approved product candidates[132] Regulatory and Accounting Considerations - The costs and timing of regulatory reviews and potential commercialization activities are uncertain and could impact financial performance[138] - The company currently has no commitments or agreements for acquiring new product candidates or entering into licensing arrangements[138] - The company has no critical accounting estimates that significantly affect its financial statements[137] - There have been no significant changes to critical accounting estimates from the previous annual report[139] - The company is classified as a "smaller reporting company" and is not required to provide certain market risk information[141] Interest and Other Income - Interest income increased to $0.7 million in Q1 2025 from$0.6 million in Q1 2024, attributed to a higher cash balance[110] - Net cash provided by financing activities was $0.4 million in Q1 2025, compared to less than$0.1 million in Q1 2024, mainly from warrant exercises[127]